novartis

Novartis buys Advanced Accelerator Applications for $3.9 billion

Novartis buys Advanced Accelerator Applications for $3.9 billion

Novartis AG (NYSE: NVS) has entered into a written agreement with French pharmaceutical company, Advanced Accelerator Applications (NASDAQ: AAAP), for $3.9 billion. Novartis shares were up 0.8 percent and Advanced Accelerator Applications shares wer..

Novartis Immunocellular Therapy Approved by FDA

Novartis Immunocellular Therapy Approved by FDA

Novartis AG (NYSE: NVS) announced Wednesday that the US Food and Drug Administration (FDA) has approved Kymriah (TM)(tisagenlecleucel) suspension for intravenous infusion, the first chimeric antigen receptor T cell (CAR-T) therapy, for the treatment..

The FDA Scheduled to Review Novartis’ Gene Therapy Drug on Wednesday

The FDA Scheduled to Review Novartis’ Gene Therapy Drug on Wednesday

Novartis AG (NYSE: NVS) is engaged in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. The U.S. Food and Drug Administration will ask a panel of advisers to focus on the safety of ..